Scholars Central

Conference abstractPublished 27 Jul 2022

Noninvasive prenatal testing A new era of aneuploidy screening

Authors: Khushboo Srivastav MD

Journal of Pharmaceutical Microbiology

Volume 8 · Issue 4 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Since ages maternal serum marker screening (double marker, quadruple test) and the respective antenatal ultrasound imaging ( NT/NB scan and anomaly scan) have been the main stay of prenatal aneuploidy screening. Both methods, however, have large false positive rates, ranging from 2% to 7%. Since its inception in 2011, millions of pregnant women in more than 90 countries have used cell-free (cf) DNA-based Non-Invasive Prenatal Testing (NIPT) to screen for fetal chromosome abnormalities and gene mutations that cause a variety of genetic disorders. NIPT is an advance method for detecting fetal chromosomal aneuploidies that examines cell-free fetal DNA in a pregnant woman's blood. While many professional associations advocate that NIPT be used as a screening approach rather than a diagnostic test, its excellent sensitivity (true positive rate) and specificity (true negative rate) make it a compelling alternative to serum screens and invasive procedures already in use

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutical Microbiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Microbiology
  • SubjectPharmaceutical Sciences
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Khushboo Srivastav MD”